NCT06948994View on ClinicalTrials.gov

A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
NeuroblastomaGD2 AntibodyAutologous NK Cell
Interventions
COMBINATION_PRODUCT

autologous NK cell plus GD2 antibody

Combination of autologous NK cells and GD2 monoclonal antibody

All Listed Sponsors
lead

Guangzhou Women and Children's Medical Center

OTHER